CLINICAL STUDIES
Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
Michael J. Domanski, MD, FACC*,
Sanjeev Sakseena, MD, FACC, FESC ,1,
Andrew E. Epstein, MD, FACC ,
Alfred P. Hallstrom, PhD,
Michael A. Brodsky, MD, FACC||,
Soo Kim, MD, FACC*,
Scott Lancaster, MS ,
Eleanor Schron, RN, MS* for the AVID Investigators
* Eastern Heart Institute—Atlantic Health System—Robert Wood Johnson School of Medicine, Newark, New Jersey, USA
University of Alabama at Birmingham, Birmingham, Alabama, USA
University of Washington, Seattle, Washington, USA
University of California, Orange, California, USA
|| Montefiore Medical Center, Bronx, New York, USA
Manuscript received October 23, 1998;
revised manuscript received January 22, 1999,
accepted February 12, 1999.
Reprint requests and correspondence: Dr. Michael J. Domanski, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 8146, Bethesda, Maryland 20892-79936
OBJECTIVES
We sought to assess the effect of baseline ejection fraction on survival difference between patients with life-threatening ventricular arrhythmias who were treated with an antiarrhythmic drug (AAD) or implantable cardioverter-defibrillator (ICD).
BACKGROUND
The Antiarrhythmics Versus Implantable Defibrillators (AVID) study demonstrated improved survival in patients with ventricular fibrillation or ventricular tachycardia with a left ventricular ejection fraction (LVEF)  0.40 or hemodynamic compromise.
METHODS
Survival differences between AAD-treated and ICD-treated patients entered into the AVID study (patients presenting with sustained ventricular arrhythmia associated with an LVEF 0.40 or hemodynamic compromise) were compared at different levels of ejection fraction.
RESULTS
In patients with an LVEF  0.35, there was no difference in survival between AAD-treated and ICD-treated patients. A test for interaction was not significant, but had low power to detect an interaction. For patients with an LVEF 0.20 to 0.34, there was a significantly improved survival with ICD as compared with AAD therapy. In the smaller subgroup with an LVEF <0.20, the same magnitude of survival difference was seen as that in the 0.20 to 0.34 LVEF subgroup, but the difference did not reach statistical significance.
CONCLUSIONS
These data suggest that patients with relatively well-preserved LVEF (0.35) may not have better survival when treated with the ICD as compared with AADs. At a lower LVEF, the ICD appears to offer improved survival as compared with AADs. Prospective studies with larger patient numbers are needed to assess the effect of relatively well-preserved ejection fraction (0.35) on the relative treatment effect of AADs and the ICDs.
|
Abbreviations and Acronyms
| | AAD | = antiarrhythmic drug | | ACE | = angiotensin converting enzyme | | AVID | = Antiarrhythmics Versus Implantable Defibrillators study | | ICD | = implantable cardioverter-defibrillator | | LVEF | = left ventricular ejection fraction | | NYHA | = New York Heart Association | | VF | = ventricular fibrillation | | VT | = ventricular tachycardia |
|
This article has been cited by other articles:
|
|
|
|
 
R. Tung, P. Zimetbaum, and M. E. Josephson
A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1111 - 1121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
e1 - e62.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation,
May 27, 2008;
117(21):
e350 - e408.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Agard, R. Lofmark, N. Edvardsson, and I. Ekman
Views of patients with heart failure about their role in the decision to start implantable cardioverter defibrillator treatment: prescription rather than participation
J. Med. Ethics,
September 1, 2007;
33(9):
514 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Passman and A. Kadish
Sudden Death Prevention With Implantable Devices
Circulation,
July 31, 2007;
116(5):
561 - 571.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-H. Kuck and S. Nisam
ICD therapy: 'the sickest benefit the most...': what about the less sick?
Europace,
July 1, 2006;
8(7):
508 - 511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J M Morgan, J C Cowan, A J Camm, and J M McComb
Sudden cardiac death: opportunities for prevention
Heart,
June 1, 2006;
92(6):
721 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Myerburg and A. Castellanos
Clinical Research Designs and Implantable Defibrillator Indications: Spend in the Beginning or Pay at the End
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
108 - 111.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J M Morgan, J Marco, L Stockx, and F Zannad
Educational governance for the regulation of industry sponsored continuing medical education in interventional and device based therapies
Heart,
June 1, 2005;
91(6):
710 - 712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Buxton, A. J. Moss, A. E. Buxton, and A. J. Moss
Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator?
Circulation,
May 17, 2005;
111(19):
2537 - 2549.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Weber, K Allikmets, and G Kornfeld
Treating electrical instability in sudden cardiac death survivors - are we looking at the right side of the coin?
Eur. Heart J.,
April 2, 2004;
25(8):
623 - 625.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. DiMarco
Implantable Cardioverter-Defibrillators
N. Engl. J. Med.,
November 6, 2003;
349(19):
1836 - 1847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Bode-Schnurbus, D Bocker, M Block, R Gradaus, A Heinecke, G Breithardt, and M Borggrefe
QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure
Heart,
October 1, 2003;
89(10):
1157 - 1162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. W. Lytle
The role of coronary revascularization in the treatment of ischemic cardiomyopathy
Ann. Thorac. Surg.,
June 1, 2003;
75(90060):
S2 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Lee, L. D. Green, P. P. Liu, P. Dorian, D. M. Newman, F. C. Grant, J. V. Tu, and D. A. Alter
Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A Meta-Analysis
J. Am. Coll. Cardiol.,
May 7, 2003;
41(9):
1573 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Buxton
The Clinical Use of Implantable Cardioverter Defibrillators: Where Are We Now? Where Should We Go?
Ann Intern Med,
March 18, 2003;
138(6):
512 - 514.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T M Kolettis, E Psarros, Z S Kyriakides, C S Katsouras, L K Michalis, and D A Sideris
Haemodynamic and catecholamine response to simulated ventricular tachycardia in man: effect of baseline left ventricular function
Heart,
March 1, 2003;
89(3):
306 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Hohnloser and B. J. Gersh
Changing Late Prognosis of Acute Myocardial Infarction: Impact on Management of Ventricular Arrhythmias in the Era of Reperfusion and the Implantable Cardioverter-Defibrillator
Circulation,
February 25, 2003;
107(7):
941 - 946.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Saksena and N. Madan
Management of the Patient With an Implantable Cardioverter-Defibrillator in the Third Millennium
Circulation,
November 19, 2002;
106(21):
2642 - 2646.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Buxton, K. L. Lee, G. E. Hafley, D. G. Wyse, J. D. Fisher, M. H. Lehmann, L. A. Pires, M. R. Gold, D. L. Packer, M. E. Josephson, et al.
Relation of Ejection Fraction and Inducible Ventricular Tachycardia to Mode of Death in Patients With Coronary Artery Disease: An Analysis of Patients Enrolled in the Multicenter Unsustained Tachycardia Trial
Circulation,
November 5, 2002;
106(19):
2466 - 2472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nisam and J. Farre
Is prophylaxis the best use of the ICD?
Eur. Heart J.,
May 1, 2002;
23(9):
700 - 705.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Parkes, J Bryant, and R Milne
Implantable cardioverter-defibrillators in arrhythmias: a rapid and systematic review of effectiveness
Heart,
May 1, 2002;
87(5):
438 - 442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Allot, C de Chillou, and N Sadoul
Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials
Eur. Heart J. Suppl.,
April 1, 2002;
4(suppl_D):
D31 - D42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C Stellbrink, A.-M Sinha, B Diem, A Auricchio, S Boccanelli, J Brugada, H Klein, J Morgan, L Padeletti, E Aliot, et al.
Implantable card ioverter-defibrillators with or without cardiac resynchronization therapy -- multiple therapy in a single device: a review with special reference to the PACIVIAN study
Eur. Heart J. Suppl.,
April 1, 2002;
4(suppl_D):
D88 - D94.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Kuhlkamp and InSync 7272 ICD World Wide Investigators
Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy
J. Am. Coll. Cardiol.,
March 6, 2002;
39(5):
790 - 797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Saoudi, J.P. Rinaldi, K. Yaici, and M. Bergonzi
Dofetilide: what role in the treatment of ventricular tachyarrhythmias?
Eur. Heart J.,
December 1, 2001;
22(23):
2141 - 2143.
[PDF]
|
|
|
|
|
|
|
G. Boriani, A. Lubinski, A. Capucci, P. Niederle, Z. Kornacewicz-Jack, A.M. Wnuk-Wojnar, M. Borggrefe, J. Brachmann, M. Biffi, G.S. Butrous, et al.
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease
Eur. Heart J.,
December 1, 2001;
22(23):
2180 - 2191.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. D. Sanders, M. A. Hlatky, N. R. Every, K. M. McDonald, P. A. Heidenreich, L. S. Parsons, and D. K. Owens
Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction
Ann Intern Med,
November 20, 2001;
135(10):
870 - 883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Viskin, A. Halkin, and J. E. Olgin
Treatable causes of sudden death: not really "treatable" or not really the cause?
J. Am. Coll. Cardiol.,
November 15, 2001;
38(6):
1725 - 1727.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. V. Huikuri, A. Castellanos, and R. J. Myerburg
Sudden Death Due to Cardiac Arrhythmias
N. Engl. J. Med.,
November 15, 2001;
345(20):
1473 - 1482.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sheldon, B. J. O'Brien, G. Blackhouse, R. Goeree, B. Mitchell, G. Klein, R. S. Roberts, M. Gent, and S. J. Connolly
Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study
Circulation,
October 2, 2001;
104(14):
1622 - 1626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Weintraub
Revascularization Versus Implantable Cardioverter-Defibrillators to Prevent Sudden Death in Patients With Severe Left Ventricular Dysfunction
Circulation,
September 25, 2001;
104(13):
1457 - 1458.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Veenhuyzen, S. N. Singh, D. McAreavey, B. J. Shelton, and D. V. Exner
Prior Coronary Artery Bypass Surgery and Risk of Death Among Patients With Ischemic Left Ventricular Dysfunction
Circulation,
September 25, 2001;
104(13):
1489 - 1493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. V. Exner, G. J. Klein, and E. N. Prystowsky
Primary Prevention of Sudden Death With Implantable Defibrillator Therapy in Patients With Cardiac Disease: Can We Afford to Do It? (Can We Afford Not To?)
Circulation,
September 25, 2001;
104(13):
1564 - 1570.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Coumel and A. A.M. Wilde
Learning From Mistakes: The Case of Clinical Electrophysiology: A Perspective on Evidence-Based Rhythmology
Circulation,
August 14, 2001;
104(7):
845 - 847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J.,
August 2, 2001;
22(16):
1374 - 1450.
[PDF]
|
|
|
|
|
|
|
R. J Myerburg and P. M Spooner
Opportunities for sudden death prevention: Directions for new clinical and basic research
Cardiovasc Res,
May 1, 2001;
50(2):
177 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Hallstrom, J. H. McAnulty, B. L. Wilkoff, D. Follmann, M. H. Raitt, M. D. Carlson, A. M. Gillis, H.-T. Shih, J. L. Powell, H. Duff, et al.
Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit
J. Am. Coll. Cardiol.,
March 15, 2001;
37(4):
1093 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Zipes
Implantable Cardioverter-Defibrillator: A Volkswagen or a Rolls Royce : How Much Will We Pay To Save A Life?
Circulation,
March 13, 2001;
103(10):
1372 - 1374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. O'Brien, S. J. Connolly, R. Goeree, G. Blackhouse, A. Willan, R. Yee, R. S. Roberts, and M. Gent
Cost-Effectiveness of the Implantable Cardioverter-Defibrillator : Results From the Canadian Implantable Defibrillator Study (CIDS)
Circulation,
March 13, 2001;
103(10):
1416 - 1421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Singh and J. S. M. Sarma
Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2001;
6(1):
69 - 87.
[PDF]
|
|
|
|
|
|
|
S. Nisam
A Prophylactic ICD? Who are the patients? What is the device?
Europace,
January 1, 2001;
3(4):
269 - 274.
[PDF]
|
|
|
|
|
|
|
R. E. Ideker, A. E. Epstein, and G. P. Walcott
Is there an optimal capacitance for defibrillation?
Europace,
January 1, 2001;
3(4):
275 - 277.
[PDF]
|
|
|
|
|
|
|
M. E. Josephson, D. J. Callans, and A. E. Buxton
The Role of the Implantable Cardioverter-Defibrillator for Prevention of Sudden Cardiac Death
Ann Intern Med,
December 5, 2000;
133(11):
901 - 910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Connolly, A. P. Hallstrom, R. Cappato, E. B. Schron, K.-H. Kuck, D. P. Zipes, H. L. Greene, S. Boczor, M. Domanski, D. Follmann, et al.
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials
Eur. Heart J.,
December 2, 2000;
21(24):
2071 - 2078.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Saksena
Implantable defibrillators in the third millennium: increasingly relegated to a standby role?
J. Am. Coll. Cardiol.,
September 1, 2000;
36(3):
828 - 831.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Moss
Implantable Cardioverter Defibrillator Therapy : The Sickest Patients Benefit the Most
Circulation,
April 11, 2000;
101(14):
1638 - 1640.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Larsen, A. Hallstrom, J. McAnulty, S. Pinski, A. Olarte, S. Sullivan, M. Brodsky, J. Powell, C. Marchant, C. Jennings, et al.
Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy
Circulation,
April 30, 2002;
105(17):
2049 - 2057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
